5. 1) var den generelle forekomst af atrieflimren 2, 5% (96 ud af 3. 852) og 1, 9% (75 ud af 3. 852) hos patienter, som fik henholdsvis Aclasta og placebo.
The rate of atrial fibrillation serious adverse events was increased in patients receiving Aclasta (1.3%) (51 out of 3,862) compared with patients receiving placebo (0.6%) (22 out of 3,852).